The TP53 tumor suppressor is the most frequently altered gene in human cancers, and has
been a major focus of oncology research. The p53 protein is a transcription factor that can …

Since its discovery over 35 years ago, MDM2 has emerged as an attractive target for the
development of cancer therapy. MDM2's activities extend from carcinogenesis to immunity to …

Immune checkpoint inhibitors (ICIs) have revolutionized the clinical management of multiple
tumours. However, only a few patients respond to ICIs, which has generated considerable …

Genomic stability in normal cells is crucial to avoid oncogenesis. Accordingly, multiple
components of the DNA damage response (DDR) operate as bona fide tumor suppressor …

Inactivation of the most important tumour suppressor gene TP53 occurs in most, if not all,
human cancers. Loss of functional wild-type p53 is achieved via two main mechanisms …

How cancer cells escape immune surveillance and resist immune checkpoint blockade
(ICB) remains to be fully elucidated. By screening candidate genes frequently gained in …

Abstract p53, which is encoded by the most frequently mutated gene in cancer, TP53, is an
attractive target for novel cancer therapies. Despite major challenges associated with this …

As a key transcription factor, the evolutionarily conserved tumor suppressor p53 (encoded
by TP 53) plays a central role in response to various cellular stresses. A variety of biological …

Over the past three decades, considerable efforts have been expended on understanding
the Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling …

JCI - SENP7 senses oxidative stress to sustain metabolic fitness and antitumor functions of
CD8+ T cells Go to JCI Insight About Editors Consulting Editors For authors Publication ethics …